Mini-organs engineered from decellularized organs repopulated with human stem cells can transform preclinical model strategies in target validation and biomarker discovery. Recellularized organs are whole humanized organs with preserved native architecture, conformity of the organ, composition of extracellular matrix and vascular matrix structures. With mini-organ models further understanding of developmental biology and assessment of potential therapeutic targets can be elucidated utilizing human induced pluripotent stem cells. As a next step, co-cultured mini-organ models could simulate pharmacokinetics and pharmacodynamics in physiological and pathological conditions. By overcoming key challenges, the development of humanized mini-organs as integrated biotechnology can address the translational gaps between in vitro, ex vivo and in vivo systems for an elevated human target validation model.

由人类干细胞再填充的脱细胞器官改造而成的微型器官可以在靶标验证和生物标记物发现中转变临床前模型策略。再细胞化的器官是具有保留的天然结构，器官的整合性，细胞外基质和血管基质结构组成的整个人源化器官。利用微型器官模型，可以利用人类诱导的多能干细胞阐明对发育生物学的进一步了解和对潜在治疗靶标的评估。下一步，共培养的微型器官模型可以在生理和病理条件下模拟药代动力学和药效学。通过克服关键挑战，作为集成生物技术的人性化微型器官的开发可以解决体外翻译之间的翻译空白，体外和体内系统用于提高的人类靶标验证模型。